Compare DNA & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNA | NPCE |
|---|---|---|
| Founded | 2008 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.6M | 490.2M |
| IPO Year | 2020 | 2021 |
| Metric | DNA | NPCE |
|---|---|---|
| Price | $7.84 | $14.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $8.50 | ★ $18.33 |
| AVG Volume (30 Days) | ★ 1.0M | 104.7K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.49 | 29.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $170,155,000.00 | $99,986,000.00 |
| Revenue This Year | N/A | $0.90 |
| Revenue Next Year | N/A | $24.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.13 |
| 52 Week Low | $5.37 | $9.22 |
| 52 Week High | $17.58 | $19.60 |
| Indicator | DNA | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 46.56 |
| Support Level | $6.38 | $13.75 |
| Resistance Level | $7.70 | $15.33 |
| Average True Range (ATR) | 0.33 | 0.55 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 70.33 | 27.12 |
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.